Neurology · 1999 · 154 citations · 4 references
Life SciencesImmunologyNeurologyImmunotherapyNeuroimmunologyVaccinologyAdverse Events Following ImmunizationCentral Nervous System ImmunityMultiple SclerosisVaccinationVaccine EfficacyVaccine-based ImmunotherapyComparative Clinical TrialsImmunization With Bacille Calmette-guérinMultiple Sclerosis ImmunopathologyMultiple Sclerosis TherapyRelapsing-remitting Multiple Sclerosis TreatmentTreatment Adverse EffectsVaccine Adjuvant Therapy
We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
4